Search results
Results from the WOW.Com Content Network
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports. September 24, 2024 at 2:17 PM ... the report added. As announced in October 2023, Sanofi is ...
In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. [2] In 2023, the company’s seat in Forbes Global 2000 was 89. [3]
In November 2023, Sanofi reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at ...
The Dow Jones Sustainability Indices (DJSI) launched in 1999, are a family of indices evaluating the sustainability performance of thousands of companies trading publicly, operated under a strategic partnership between S&P Dow Jones Indices and RobecoSAM (Sustainable Asset Management) [1] of the S&P Dow Jones Indices. They are the longest ...
Olivier Nataf Global Head, Oncology “This approval marks an important milestone for Sanofi in China. The results of the ICARIA-MM phase 3 study, coupled with the real-world IsaFiRsT study, highlight the benefit of Sarclisa for patients living with multiple myeloma and the importance of innovative regulatory pathways for timely access to ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of ...
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...
The company was reportedly the center of a bidding war between Amgen, Johnson & Johnson and Sanofi. [18] In May 2023, the Federal Trade Commission said it would sue to block the deal in an attempt to control drug prices. [17] [19] [20] The acquisition was completed in October 2023 after mutually resolving the litigation. [5]